Recent advances in understanding and managing adenosine deaminase and purine nucleoside phosphorylase deficiencies

Current Opinion in Allergy and Clinical Immunology

Volumn 13, Issue 6, 2013, Pages 630-638

  Grunebaum, Eyal ^a   Cohen, Amos ^a   Roifman, Chaim M ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Adenosine deaminase; Immunodeficiency; Purine nucleoside phosphorylase; Systemic

Indexed keywords

ADENOSINE DEAMINASE; PURINE NUCLEOSIDE PHOSPHORYLASE;

ADENOSINE DEAMINASE DEFICIENCY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE DISEASE; BONE MARROW DISEASE; BRAIN DISEASE; DISEASE ASSOCIATION; ENZYME REPLACEMENT; GENE THERAPY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNOTHERAPY; LUNG DISEASE; NEUTROPENIA; NEWBORN SCREENING; NONHUMAN; PRIORITY JOURNAL; PURINE NUCLEOSIDE PHOSPHORYLASE DEFICIENCY; REVIEW;

ADENOSINE DEAMINASE; AGAMMAGLOBULINEMIA; ANIMALS; ENZYME REPLACEMENT THERAPY; HUMANS; LYMPHOCYTE ACTIVATION; MACROPHAGES, ALVEOLAR; PURINE-NUCLEOSIDE PHOSPHORYLASE; PURINE-PYRIMIDINE METABOLISM, INBORN ERRORS; PURINES; PURKINJE CELLS; SEVERE COMBINED IMMUNODEFICIENCY; T-LYMPHOCYTES;

EID: 84889880502     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000006     Document Type: Review

References (78)

1. Redelman D, Bluestein HG, Cohen AH, et al. Deoxyadenosine (AdR) inhibition of newly activated lymphocytes: blockade at the G0-G1 interface. J Immunol 1984; 132:2030-2038.
2. Arpaia E, Benveniste P, Di Cristofano A, et al. Mitochondrial basis for immune deficiency: evidence from purine nucleoside phosphorylase-deficient mice. J Exp Med 2000; 191:2197-2208.
3. Cohen A, Gudas LJ, Ammann AJ, et al. Deoxyguanosine triphosphate as a possible toxic metabolite in the immunodeficiency associated with purine nucleoside phosphorylase deficiency. J Clin Invest 1978; 61:1405-1409.
4. Shimoyama RK, Seto S, Mori C. Protection by various deoxynucleosides against deoxyadenosine-induced DNA damage in adenosine deaminaseinactivated lymphocytes. Mol Genet Metab 1999; 68:455-460.
5. Gangi-Peterson L, Sorscher DH, Reynolds JW, et al. Nucleotide pool imbalance and adenosine deaminase deficiency induce alterations of N-region insertions during V(D)J recombination. J Clin Invest 1999; 103:833-841.
6. Giblett ER, Anderson JE, Cohen F, et al. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972; 2:1067-1069.
7. Giblett ER, Ammann AJ, Wara DW, et al. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1975; 1:1010-1013.
8. Santisteban I, Arredondo-Vega FX, Kelly S, et al. Three new adenosine deaminase mutations that define a splicing enhancer and cause severe and partial phenotypes: implications for evolution of a CpG hotspot and expression of a transduced ADA cDNA. Hum Mol Genet 1995; 4:2081-2087.
9. Sanchez JJ, Monaghan G, Børsting C, et al. Carrier frequency of a nonsense mutation in the adenosine deaminase (ADA) gene implies a high incidence of ADA-deficient severe combined immunodeficiency (SCID) in Somalia and a single, common haplotype indicates common ancestry. Ann Hum Genet 2007; 71 (Pt 3):336-347.
10. Walker PL, Corrigan A, Arenas M, et al. Purine nucleoside phosphorylase deficiency: A mutation update. Nucleosides Nucleotides Nucleic Acids 2011; 30:1243-1247.
11. Shovlin CL, Simmonds HA, Fairbanks LD, et al. Adult onset immunodeficiency caused by inherited adenosine deaminase deficiency. J Immunol 1994; 153:2331-2339.
12. Ozsahin H, Arredondo-Vega FX, Santisteban I, et al. Adenosine deaminase deficiency in adults. Blood 1997; 89:2849-2855.
13. Felgentreff K, Perez-Becker R, Speckmann C, et al. Clinical and immunological manifestations of patients with atypical severe combined immunodeficiency. Clin Immunol 2011; 141:73-82.
14. Parvaneh N, Ashrafi MR, Yeganeh M, et al. Progressive multifocal leukoencephalopathy in purine nucleoside phosphorylase deficiency. Brain Dev 2007; 29:124-126.
15. Aytekin C, Dogu F, Tanir G, et al. Purine nucleoside phosphorylase deficiency with fatal course in two sisters. Eur J Pediatr 2010; 169:311-314.
16. Somech R, Lev A, Grisaru-Soen G, et al. Purine nucleoside phosphorylase deficiency presenting as severe combined immune deficiency. Immunol Res 2013; 56:150-154. This report demonstrates the potential effects of PNP deficiency on T and B lymphocytes.
17. Somech R, Lev A, Simon AJ, et al. T-and B-cell defects in a novel purine nucleoside phosphorylase mutation. J Allergy Clin Immunol 2012; 130:539-542.
18. Serana F, Sottini A, Chiarini M, et al. The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency. J Immunol 2010; 185:7713-7722.
19. Poliani PL, Facchetti F, Ravanini M, et al. Early defects in human T-cell development severely affect distribution and maturation of thymic stromal cells: possible implications for the pathophysiology of Omenn syndrome. Blood 2009; 114:105-108.
20. Cassani B, Mirolo M, Cattaneo F, et al. Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients. Blood 2008; 111:4209-4219.
21. Yu Y, Arora A, Min W, et al. EdU incorporation is an alternative nonradioactive assay to [(3)H]thymidine uptake for in vitro measurement of mice T-cell proliferations. J Immunol Methods 2009; 350:29-35.
22. Roifman CM, Somech R, Kavadas F, et al. Defining combined immunodeficiency. J Allergy Clin Immunol 2012; 130:177-183. This single center study of 103 patients is the first to define typical versus less typical T cell deficiencies such as PNP deficiency.
23. Papinazath T, Min W, Sujiththa S, et al. Effects of purine nucleoside phosphorylase deficiency on thymocyte development. J Allergy Clin Immunol 2011; 128:854-863.
24. Schmitt TM, Zún iga-Pflu cker JC. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity 2002; 17:749-756.
25. Somech R, Lai YH, Grunebaum E, et al. Polyethylene glycol-modified adenosine deaminase improved lung disease but not liver disease in partial adenosine deaminase deficiency. J Allergy Clin Immunol 2009; 124:848-850.
26. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360:447-458.
27. Sauer AV, Brigida I, Carriglio N, Aiuti A. Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency. Front Immunol 2012; 3:265.
28. Sauer AV, Brigida I, Carriglio N, et al. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood 2012; 119:1428-1439. This study investigates the contribution of T cells abnormalities to the development of autoimmunity in ADA deficiency.
29. Roifman CM, Zhang J, Atkinson A, et al. Adenosine deaminase deficiency can present with features of Omenn syndrome. J Allergy Clin Immunol 2008; 121:1056-1058.
30. Sauer AV, Morbach H, Brigida I, et al. Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy. J Clin Invest 2012; 122:2141-2152. This study investigates the contribution of B cells abnormalities to the development of autoimmunity in ADA deficiency.
31. Ho nig M, Albert MH, Schulz A, et al. Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood 2007; 109:3595-3602.
32. Grunebaum E, Mazzolari E, Porta F, et al. Bone marrow transplantation for severe combined immune deficiency. JAMA 2006; 295:508-518.
33. Nakaoka H, Kanegane H, Taneichi H, et al. Delayed onset adenosine deaminase deficiency associated with acute disseminated encephalomyelitis. Int J Hematol 2012; 95:692-696.
34. Nofech-Mozes Y, Blaser SI, Kobayashi J, et al. Neurologic abnormalities in patients with adenosine deaminase deficiency. Pediatr Neurol 2007; 37:218-221.
35. Ozkinay F, Pehlivan S, Onay H, et al. Purine nucleoside phosphorylase deficiency in a patient with spastic paraplegia and recurrent infections. J Child Neurol 2007; 22:741-743.
36. Dehkordy SF, Aghamohammadi A, Ochs HD, Rezaei N. Primary immunodeficiency diseases associated with neurologic manifestations. J Clin Immunol 2012; 32:1-24.
37. Camici M, Micheli V, Ipata PL, Tozzi MG. Pediatric neurological syndromes and inborn errors of purine metabolism. Neurochem Int 2010; 56:367-378.
38. Mansouri A, Min W, Cole CJ, et al. Cerebellar abnormalities in purine nucleoside phosphorylase deficient mice. Neurobiol Dis 2012; 47:201-209. This is the first study investigating the effects of PNP deficiency on the brain, using a unique PNP-deficient mouse model.
39. Booth C, Algar VE, Xu-Bayford J, et al. Noninfectious lung disease in patients with adenosine deaminase deficient severe combined immunodeficiency. J Clin Immunol 2012; 32:449-453.
40. Grunebaum E, Cutz E, Roifman CM. Pulmonary alveolar proteinosis in patients with adenosine deaminase deficiency. J Allergy Clin Immunol 2012; 129: 1588-1593. This is the first study showing pulmonary alveolar proteinosis as a cause for the frequent noninfectious lung abnormalities in ADA-deficient patients.
41. Carey B, Trapnell BC. The molecular basis of pulmonary alveolar proteinosis. Clin Immunol 2010; 135:223-235.
42. Blackburn MR, Datta SK, Kellems RE. Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J Biol Chem 1998; 273:5093-5100.
43. Blackburn MR, Volmer JB, Thrasher JL, et al. Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction. J Exp Med 2000; 192:159-170.
44. Dhanju P, Min W, Ackerely C, et al. Pulmonary alveolar proteinosis in adenosine deaminase deficient mice. J Allergy Clin Immunol; submitted for Publication. Under review.
45. Manson D, Diamond L, Oudjhane K, et al. Characteristic scapular and rib changes on chest radiographs of children with ADA-deficiency SCIDS in the first year of life. Pediatr Radiol 2013; 43:589-592.
46. Sauer AV, Mrak E, Hernandez RJ, et al. ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency. Blood 2009; 114:3216-3226.
47. Notarangelo LD. Primary immunodeficiencies (PIDs) presenting with cytopenias. Hematol Am Soc Hematol Educ Program 2009; 139-143.
48. Dror Y, Grunebaum E, Hitzler J, et al. Purine nucleoside phosphorylase deficiency associated with a dysplastic marrow morphology. Pediatr Res 2004; 55:472-477.
49. Nomura K, Hoshino A, Miyawaki T, et al. Neutropenia and myeloid dysplasia in a patient with delayed-onset adenosine deaminase deficiency. Pediatr Blood Cancer 2013; 60:885-886.
50. Sokolic R, Maric I, Kesserwan C, et al. Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency. Blood 2011; 118:2688-2694.
51. Puck JM. Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles. J Allergy Clin Immunol 2012; 129:607-616.
52. van Kuilenburg AB, Zoetekouw L, Meijer J, Kuijpers TW. Identification of purine nucleoside phosphorylase deficiency in dried blood spots by a nonradiochemical assay using reversed-phase high-performance liquid chromatography. Nucleosides Nucleotides Nucleic Acids 2010; 29:466-470.
53. van Kuilenburg AB, Zoetekouw L, Meijer J, Kuijpers TW. Determination of adenosine deaminase activity in dried blood spots by a nonradiochemical assay using reversed-phase high-performance liquid chromatography. Nucleosides Nucleotides Nucleic Acids 2010; 29:461-465.
54. Azzari C, la Marca G, Resti M. Neonatal screening for severe combined immunodeficiency caused by an adenosine deaminase defect: A reliable and inexpensive method using tandem mass spectrometry. J Allergy Clin Immunol 2011; 127:1394-1399.
55. la Marca G, Canessa C, Giocaliere E, et al. Tandem mass spectrometry, but not T-cell receptor excision circle analysis, identifies newborns with late-onset adenosine deaminase deficiency. J Allergy Clin Immunol 2013; 131:1604-1610. This study demonstrates that mass spectrometry is superior to TREC testing in identifying ADA-deficient newborns.
56. Hassan A, Booth C, Brightwell A, et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood 2012; 120:3615-3624. This is the largest multicentre study until now that assesses the outcome of hematopoietic stem cell transplantation in 106 ADA-deficient patients.
57. Gaspar HB, Cooray S, Gilmour KC, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 2011; 3:97.
58. Carbonaro DA, Jin X, Wang X, et al. Gene therapy/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction. Blood 2012; 120:3677-3687. This study evaluates the contributions of enzyme replacement and cytoreduction to the success of gene therapy and bone marrow transplantation in ADA deficiency using ADA-deficient mice.
59. Delicou S, Kitra-Roussou V, Peristeri J, et al. Successful HLA-identical hematopoietic stem cell transplantation in a patient with purine nucleoside phosphorylase deficiency. Pediatr Transplant 2007; 11:799-803.
60. Aytekin C, Yuksek M, Dogu F, et al. An unconditioned bone marrow transplantation in a child with purine nucleoside phosphorylase deficiency and its unique complication. Pediatr Transplant 2008; 12:479-482.
61. Singh V. Cross correction following haemopoietic stem cell transplant for purine nucleoside phosphorylase deficiency: engrafted donor-derived white blood cells provide enzyme to residual enzyme-deficient recipient cells. JIMD Rep 2012; 6:39-42.
62. Candotti F, Shaw KL, Muul L, et al. Gene therapy for adenosine deaminasedeficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 2012; 120:3635-3646. This study compares different gene therapy strategies for ADA deficiency and demonstrates the important role of approaches.
63. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296:2410-2413.
64. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. Gene therapy of primary T cell immunodeficiencies. Gene 2013; 525:170-173.
65. Kesserwan C, Sokolic R, Cowen EW, et al. Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase-deficient severe combined immune deficiency. J Allergy Clin Immunol 2012; 129:762-769e1. This is the first large study demonstrating high incidence of tumors among patients with partially corrected ADA deficiency.
66. Grunebaum E, Chung CT, Dadi H, et al. Purine metabolism, immune reconstitution, and abdominal adipose tumor after gene therapy for adenosine deaminase deficiency. J Allergy Clin Immunol 2011; 127:1417-1419.
67. Montiel-Equihua CA, Zhang L, Knight S, et al. The b-globin locus control region in combination with the EF1a short promoter allows enhanced lentiviral vector-mediated erythroid gene expression with conserved multilineage activity. Mol Ther 2012; 20:1400-1409.
68. Liao P, Toro A, Min W, et al. Lentivirus gene therapy for purine nucleoside phosphorylase deficiency. J Gene Med 2008; 10:1282-1293.
69. Rich KC, Majias E, Fox IH. Purine nucleoside phosphorylase deficiency: improved metabolic and immunologic function with erythrocyte transfusions. N Engl J Med 1980; 303:973-977.
70. Hershfield MS, Buckley RH, Greenberg ML, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 1987; 316:589-596.
71. Booth C, Gaspar HB. Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID). Biologics 2009; 3:349-358.
72. Husain M, Grunebaum E, Naqvi A, et al. Burkitt's lymphoma in a patient with adenosine deaminase deficiency-severe combined immunodeficiency treated with polyethylene glycol-adenosine deaminase. J Pediatr 2007; 151:93-95.
73. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55:1189-1193.
74. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 1988; 55:1179-1188.
75. Toro A, Paiva M, Ackerley C, Grunebaum E. Intracellular delivery of purine nucleoside phosphorylase (PNP) fused to protein transduction domain corrects PNP deficiency in vitro. Cell Immunol 2006; 240:107-115.
76. Toro A, Grunebaum E. TAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in mice. J Clin Invest 2006; 116:2717-2726.
77. Benveniste P. Cohen A. p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency. Proc Natl Acad Sci U S A 1995; 92:8373-8377.
78. Joachims ML, Marble PA, Laurent AB, et al. Restoration of adenosine deaminase-deficient human thymocyte development in vitro by inhibition of deoxynucleoside kinases. J Immunol 2008; 181:8153-8161.